Lung Cancer Video Library 2020 - LEVY - Immunotherapy Combinations for Advanced NSCLC

Article and Video CATEGORIES

Cancer Journey

ABOUT

Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology for Johns Hopkins University School of Medicine. Dr. Levy is board certified in medical oncology and hematology by the American Board of Internal Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.

For this new addition to the GRACE Lung Cancer Video Library, Dr. Ben Levy joins GRACE to discuss current updates in treatments for non small cell lung cancer.

In this video, Dr. Levy discusses updated information on immunotherapy combinations for advanced nsclc.

To join the conversation, visit https://cancergrace.org/forum.

Video Language

English

Please feel free to offer comments and raise questions in our
discussion forums.

Join The conversation

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.